BioNTech price target lowered to $130 from $145 at Citi
Citi lowered the firm’s price target on BioNTech (BNTX) to $130 from $145 and keeps a Buy rating on the shares. The departures of the company’s co-founders is a surprise but the share selloff offers a good entry point, the analyst tells investors in a research note. Citi says BioNTech’s pipeline has multiple Phase 3 opportunities.
Read More on BNTX:
- Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
- BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
- Jefferies cuts BioNTech price target, says stock is cheap
- Clear Street lowers BioNTech price target, says buy on weakness
- BioNTech falls -19.9%
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3 Altcoins to Watch in the First Week of November 2026
Trump and Jim Cramer Defend SpaceX as Musk Wants to Enter the Telecom Market
Gold’s lost haven allure to swing back into view on deficit woes
Crypto prices
More
